RxDoctor Payments Data

Jamie Tueth, DO

Internal Medicine · O Fallon, MONPI 1619100989

Payments from drug & device makers

$533in general payments, 2019–2025

Across 34 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$169
  • Pfizer$109
  • Lilly USA, LLC$65
  • AbbVie$52
  • Novo Nordisk$45
  • Boehringer Ingelheim$28
  • plus $66 from 4 others

What the payments were for

  • Food & beverage$533100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$533 in reported general payments places this provider in the 65th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$83,847
Medicare patients
277
Services billed
1,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide166$198,046
EliquisApixaban105$117,189
TrulicityDulaglutide66$66,566
MounjaroTirzepatide51$58,641
JardianceEmpagliflozin38$56,380
MyrbetriqMirabegron72$51,870
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$45,463
XareltoRivaroxaban41$38,376
ArexvyRsvpref3 Antigen/As01e/Pf100$25,553
LinzessLinaclotide26$25,100
Tresiba Flextouch U-100Insulin Degludec52$24,180
ProliaDenosumab12$20,457
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog35$19,746
JanuviaSitagliptin Phosphate17$15,920
Semglee (Yfgn) PenInsulin Glargine-Yfgn23$10,857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$45$198,046166 claims
Lilly USA, LLCTrulicity, Mounjaro$65$125,206117 claims
PfizerEliquis$109$117,189105 claims
GSKTrelegy Ellipta, Arexvy, Anoro Ellipta, Breo Ellipta$169$90,262175 claims
Boehringer IngelheimJardiance, Tradjenta$28$62,92450 claims
AbbVieLinzess, Synthroid$52$31,468115 claims
AmgenProlia$16$20,45712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in O Fallon

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →